ArticleFrontiers in neurology
Analysis of the incidence status and risk factors for immune-mediated neuropathies: a single-center case-control study.
Article in Frontiers in neurology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Acute Management of Guillain-Barré Syndrome: A Narrative Review.Archives of internal medicine research · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To investigate the epidemiological characteristics of immune-mediated neuropathies (primarily including Guillain-Barré Syndrome and Chronic Inflammatory Demyelinating Polyradiculoneuropathy) and systematically analyze their associated risk factors, providing a theoretical basis for disease prevention and early intervention. Methods: A retrospective study was conducted. 158 patients with immune-mediated neuropathies admitted to our hospital between January 2020 and December 2023 were selected as the case group, while 160 healthy individuals undergoing physical examinations during the same period were selected as the control group. Demographic data and clinical records (including history of preceding infections, vaccination history, history of comorbid diseases, etc.) were collected and compared for all subjects. Univariate analysis and multivariate logistic regression analysis were used to identify independent risk factors for immune-mediated neuropathies. Results: The annual incidence of immune-mediated neuropathies was 1.24 per 100,000, with a bimodal age distribution (20-30 years and 50-70 years). The incidence was slightly higher in males than in females (1.5:1). Univariate analysis showed statistically significant differences ( Conclusion: The onset of immune-mediated neuropathies is closely related to various environmental and individual factors. Preceding infections (especially
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.